Company

Program

Terms & Policies

© 2025 TikTok

fdagovph

FDA Philippines

8Following
599Followers
2941Likes

Official TikTok Account of FDA Philippines

Videos

Liked

Pagbati mula kay First Lady Marie Louise "Liza" Araneta Marcos para sa ika-60 anibersaryo ng Food and Drug Administration (FDA). #FDA60thAnniversary #FDADiamond #FDA #Educate #Regulate #Monitor created by FDA Philippines with FDA Philippines’s original sound - FDA Philippines

318

President Ferdinand "Bongbong" Romualdez Marcos Jr. extends his warmest greetings to FDA Director General Dr. Samuel A. Zacate on his birthday today. #BagongPilipinas #BagongFDA created by FDA Philippines with FDA Philippines’s original sound - FDA Philippines

Bagong Pilipino #FDA #BagongPilipinas created by FDA Philippines with FDA Philippines’s original sound - FDA Philippines

Recap | During the MOA Signing between FDA and Province of Northern Samar created by FDA Philippines with FDA Philippines’s original sound - FDA Philippines

652

In a significant step toward empowering Micro, Small, and Medium Enterprises (MSMEs), the Food and Drug Administration (FDA) has officially partnered with the City Government of Bislig through the signing of a Memorandum of Agreement (MOA) for the Bigyang-Halaga, Bangon MSMEs (BBMSMEs) Program on March 17, 2025, at Ampero Hall, Bislig City, Surigao del Sur. This collaboration underscores the FDA’s commitment to strengthening food safety standards and ensuring regulatory compliance among local businesses. Under the BBMSMEs Program, the FDA provides technical assistance, capacity-building initiatives and regulatory support to help MSMEs comply with Good Manufacturing Practices (GMP) and other essential safety protocols. By streamlining the processes for securing authorizations such as License to Operate (LTO) and Certificate of Product Registration (CPR), the program aims to enhance market opportunities for local entrepreneurs. FDA Director General Dr. Samuel Zacate emphasized the agency’s dedication to expanding the program’s reach beyond Bislig City, ensuring that even the most remote areas of the country receive government support. “In line with the directive of President Ferdinand 'Bongbong' R. Marcos Jr., the FDA remains steadfast in bringing government services closer to the people. Our goal is to empower MSMEs not only in this province but across the country by improving their access to regulatory services. Through this kind of collaboration with local government units (LGUs), the Department of Science and Technology (DOST), the Department of Trade and Industry (DTI), and state universities, we will facilitate laboratory testing, capacity-building programs, and a more efficient regulatory compliance system,” he stated. The MOA signing ceremony was attended by key officials, including Bislig City Mayor Florencio C. Garay, Vice Mayor Alfredo J. Carmelo, FDA OIC-Deputy Director General Jesusa Joyce Cirunay, and Mindanao East Cluster Director Deborah S. Legaspi. Through this strengthened alliance, the FDA reaffirms its mission to uplift MSMEs, foster economic resilience, and cultivate a more competitive business environment. By prioritizing food safety and regulatory excellence, the agency remains committed to ensuring that Filipino products meet the highest standards, paving the way for sustainable growth and expanded opportunities for local businesses. #FDA #BagongPilipinas #BagongMukhaNgFDA

731

FDA STRENGTHENS HEALTH SUPPLEMENTS REGULATION FOR CONSUMER SAFETY The Food and Drug Administration (FDA) met with the Health and Dietary Supplement Association of the Philippines (HADSAP) to reinforce regulatory standards and industry compliance for health supplements on March 11, 2025 at the Office of the Director General Conference Room. During the meeting, FDA officials outlined key initiatives, including the Southern Cross Initiative and Task Force Thomson, which both focus on policy development for Traditional Medicines and Health Supplements. The discussions emphasized the distinct regulatory requirements for food and health supplements. To foster transparency and industry collaboration, the FDA drafted an Administrative Order (AO) detailing GMP and registration requirements for health supplements. This document is open for stakeholder comments on the FDA website, with public consultations scheduled within March. Recognizing the challenges that small and medium enterprises (SMEs) face in complying with regulatory updates, HADSAP sought a comprehensive list of stakeholders, particularly micro, small, and medium enterprises (MSMEs), that may qualify for membership. To ensure adherence to regulatory requirements, HADSAP established a rigorous compliance process. In line with this initiative, HADSAP formally requested the support of the FDA to reinforce its efforts and promote broader industry participation. The FDA remains steadfast in its mission to safeguard public health while supporting responsible industry growth. Stakeholders are encouraged to stay informed and participate in the consultation process by visiting www.fda.gov.ph. #FDAPhilippines #Educate #Regulate #Monitor

768

In celebration of the 43rd anniversary of the Department of Science and Technology - Philippine Council for Health Research and Development (DOST-PCHRD), the Food and Drug Administration (FDA) joined this event at the Sheraton Manila Hotel, Newport World Resorts, Pasay City on 17 March 2025. This was spearheaded by DOST Secretary Renato Solidum Jr and PCHRD Executive Director Dr. Jaime C. Montoya. The event, themed “Building a Healthier & Wealthier Future: Advancing Research Utilization for Greater Impact,” focused on translating health research into practical applications. The FDA reaffirmed its commitment to ensuring that research-driven health product regulation is safe, effective, and accessible to Filipinos. Dr. Irene V. Florentino-Fariñas, Director III of the FDA Policy and Planning Service, participated as a panelist in a plenary session led by Dr. Kenneth Y. Hartigan-Go of the Ateneo Policy Center. She mentioned the research initiatives of the agency, including guidelines on research conduct and a manual of procedures for research management. Dr. Fariñas emphasized the FDA’s role in supporting researchers through data-sharing policies and regulatory guidance. Representatives from the Department of Health and the Philippine Chamber of Commerce and Industry were also invited as panelists to address issues and concerns on the relevance of health research in policy formulation and product consumption, respectively. The FDA continues to support local researchers and small-scale innovators by providing training on regulatory requirements. These efforts align with the agency’s mission to safeguard public health while fostering innovation in the health sector. With its proactive approach, the FDA remains a key partner in health research, ensuring that all health products meet the highest safety and quality standards. #FDA #DOST #DOSTPCHRD #Educate #Regulate #Monitor #foryoupage

681

In celebration of World Consumer Rights Day 2025, the Food and Drug Administration Policy and Planning Service-Policy Dissemination and Training Division (FDA-PPS-PDTD) gave a lecture for the health personnel and Consumer Welfare Office (CWO) staff of Parañaque City as part of their Gender and Development Seminar. The event, held on March 14, 2025, at the Legislative Building, embraced this year’s theme, “A Just Transition to Sustainable Lifestyle.” The seminar provided an insightful discussion on the regulations concerning adulterated food, equipping local personnel with vital knowledge to safeguard public health. Ms. Estrellita B. Pastolero, PPS-PDTD Chief, opened the session with a comprehensive lecture on the Overview of the Food and Drug Administration. Her presentation outlined the FDA’s pivotal role in ensuring health products' safety, efficacy, and quality, including prepackaged and processed food products. Ms. Derlyn B. Clacio, HEPO II, delivered an in-depth discussion on Adulterated Food and Its Regulation. She elaborated on the associated risks, the legal framework governing food safety, and the stringent measures enforced to protect consumers from health hazards. The seminar was well-attended, with ninety-five (95) personnel from the sixteen (16) barangays of Parañaque City participating. The attendees were Barangay Health Workers and Consumer Welfare Office personnel, all of whom are crucial in community health and consumer protection. By fostering awareness and strengthening regulatory knowledge, the FDA continues to uphold its mission of protecting public health and empowering communities toward a sustainable and consumer-conscious future. #FDA #Educate #Regulate #Monitor #worldconsumerrightsday #foryoupage

632

FDA, MAS PINALAWAK ANG LISTAHAN NG MGA VAT-EXEMPT NA GAMOT PARA SA MAS ABOT-KAYANG KALUSUGAN NG PILIPINO Alinsunod sa Seksyon 12 ng Republic Act (RA) No. 11534 o mas kilala bilang “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act”, ang ilang piling gamot para sa kanser, diabetes, hypertension, tuberculosis, mental illness, at high cholesterol ay exempted sa Value-Added Tax (VAT). Tinukoy ng Food and Drug Administration (FDA) ang listahan ng VAT-exempt na health products upang maisumite ang mga ito sa iba pang ahensyang nagpapatupad nito tulad ng Bureau of Internal Revenue (BIR), Bureau of Customs, at Department of Trade and Industry. Narito ang update sa listahan ng VAT-exempt medicines alinsunod sa R.A No. 11534, na naging epektibo noong ika-10 ng Disyembre 2024: A. Mga Gamot Para sa Diabetes: • Gemigliptin (as tartrate sesquihydrate) + Metformin hydrochloride: Film-Coated Tablet (50 mg/500 mg). • Gemigliptin (as tartrate sesquihydrate): Film-Coated Tablet (50 mg). • Sitagliptin (as phosphate monohydrate) + Metformin Hydrochloride: Extended Release Film Coated Tablet (100 mg/1g) • Sitagliptin Phosphate + Metformin Hydrochloride: Extended Release Film Coated Tablet (100 mg/1g) B. Mga Gamot Para sa Hypertension: • Amlodipine (as besilate): Tablet (20 mg). C. Mga Gamot Para sa High Cholesterol: • Amlodipine (as besylate) + Atorvastatin (as calcium): Film-Coated Tablet (5 mg/20 mg) • Amlodipine (as besylate) + Atorvastatin (as calcium): Tablet (5 mg/20 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Tablet (5 mg/10 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Tablet (5 mg/40 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Tablet (10 mg/20 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Tablet (10 mg/40 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Tablet (10 mg/80 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Film-Coated Tablet (5 mg/20 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Film-Coated Tablet (10 mg/10 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Film-Coated Tablet (10 mg/40 mg) • Amlodipine (as besilate) + Atorvastatin (as calcium): Film-Coated Tablet (10 mg/80 mg) D. Mga Gamot Para sa Mental Illness: • Risperidone: Orodispersible Tablet (4 mg) Generic Name Dosage Strength Dosage Form Risperidone 4 mg Orodispersible Tablet Patuloy na sinusuportahan ng FDA ang abot-kayang healthcare para sa lahat ng Pilipino. Sa pamamagitan ng pagpapalawig ng listahan ng mga VAT-exempt na gamot, layunin ng FDA na mabawasan ang gastusin sa gamutan at mapadali ang access sa dekalidad na pangangalaga, lalo na para sa mga nangangailangan ng life-saving medications. Para sa karagdagang impormasyon at katanungan, maaaring makipag-ugnayan sa FDA Policy and Planning Service (PPS) sa pamamagitan ng email: pps@fda.gov.ph. #FDAPhilippines #Educate #Regulate #Monitor

773

The Food and Drug Administration (FDA) initiated a meeting with the Department of Trade and Industry-Bureau of Small and Medium Enterprise Development (DTI-BSMED) on March 13, 2025 in Makati City to discuss future collaborations on programs for Micro, Small, and Medium Enterprises (MSMEs). Both agencies aim to help small businesses grow by improving regulations and make compliance with health and safety standards easier. As part of these efforts, the FDA has introduced two new Administrative Orders to simplify licensing and regulatory procedures for businesses. Administrative Order No. 2024-0015 provides updated rules and requirements for obtaining an FDA license to operate, replacing the previous guidelines under Administrative Order No. 2020-0017. Meanwhile, Administrative Order No. 2024-0016 implements a revised schedule of fees and charges to make regulatory compliance more accessible for MSMEs. These changes are aimed at promoting efficiency and transparency while ensuring that small businesses can navigate the regulatory landscape with greater ease. Key officials in the meeting included Dr. Irene V. Florentino-Fariñas, Director III of the FDA Policy and Planning Service (FDA-PPS) and Ms. Estrellita B. Pastolero, Health Education and Promotion Officer V of the PPS-Policy Dissemination and Training Division. Representing DTI were Assistant Secretary Grace F. Baluyan and BSMED Director Emma C. Asusano. Both agencies committed to working together to create a better business environment for MSMEs, ensuring their growth and success. #FDA #DTI #MSMEs #Educate #Regulate #Monitor #foryou #fypage #trend

233

Matagumpay na nagsagawa ng webinar ang Food and Drug Administration (FDA), sa pangunguna ng Policy and Planning Service (PPS) - Policy Dissemination and Training Division-Advocacy Section bilang paggunita sa Rabies Awareness Month ngayong Marso. Ito ay may pamagat na “Biting Truth, Saving Lives: Rabies Awareness Kontra Pekeng Bakuna — Ang Katotohanang Nakakagigil” na dinaluhan ng mahigit limandaang kalahok noong 11 Marso 2025. Tampok sa webinar ang mga eksperto mula sa Department of Health - Research Institute for Tropical Medicine (DOH-RITM) at FDA Center for Drug Regulation and Research (FDA-CDRR). Tinalakay dito ang mahahalagang paksa gaya ng mga sintomas ng rabies, paano ito naipapasa, pag-iwas sa pamamagitan ng pagbabakuna at ang mga tungkuling ginagampanan ng FDA sa regulasyon ng mga bakuna laban sa rabies. Isang mahalagang bahagi rin ng webinar ang pagbibigay-kaalaman sa publiko kung paano protektahan ang sarili laban sa mapanganib na pekeng bakuna at ang tamang proseso sa pag-uulat ng mga ito. Alinsunod sa mandato ng Republic Act No. 9711, naglalayon ang inisyatibang ito na tiyakin na ligtas, mabisa at de kalidad ang mga produktong pangkalusugan, kabilang na ang mga bakuna, sa pakikipagtulungan sa iba’t ibang ahensya. Bilang bahagi ng kampanya sa pagpapalawak ng kaalaman tungkol sa rabies, inilunsad din ng FDA ang mga Information, Education, and Communication (IEC) materials para sa Rabies Awareness Month na makikita sa FDA website at mga opisyal social media accounts nito (https://www.fda.gov.ph/information-education-and-communication-iec/). Nagpapasalamat ang FDA sa 551 na lumahok sa webinar, kabilang na ang mga kinatawan mula sa LGUs, mga Pamantasan, Animal Bite Treatment Centers (ABTCs), Animal Bite Clinics (ABCs), at mga Rural Health Units (RHUs) sa Luzon, Visayas, at Mindanao. Patuloy na naninindigan ang FDA sa pagsusulong ng pagpapalakas ng regulasyon at pagpapalawak ng kamalayan ng publiko bilang suporta sa pambansang layunin na mapababa at tuluyang masugpo ang rabies sa bansa. #FDA #FDAAdvocay #RabiesAwarenessMonth #Rabies #Educate #Regulate #Monitor #fypage

672

The Food and Drug Administration (FDA) and the Department of Trade and Industry (DTI) held talks on collaboration to provide stronger support for Micro, Small, and Medium Enterprises (MSMEs) and further improve supply chain processes. The meeting transpired at the FDA Main Office in Alabang on 11 March 2025 when DTI Undersecretary Mary Jean T. Pacheco, who leads the Supply Chain and Logistics Group (SCLG), paid a courtesy visit to FDA Director General Dr. Samuel Zacate. It aimed at discussing ways to support MSMEs by addressing supply chain challenges that affect various products being regulated by the FDA. Undersecretary Pacheco emphasized that the SCLG is committed to ensuring the smooth movement of goods, promoting trade efficiency, and maintaining economic stability. By working together, however, both agencies ensure that essential products, particularly those crucial to public health, reach consumers without unnecessary delays. During the meeting, Director General Zacate shared his initiative program, Bigyang-halaga Bangon Micro, Small, Medium Enterprises (BBMSME), which focuses on supporting MSMEs by providing technical assistance and other resources to help them thrive in the market. This collaboration between the FDA and DTI reflects a shared commitment to consumer welfare, public health, and economic growth. #FDA #BagongPilipinas #BagongMukhaNgFDA

731

In a decisive move to empower local Micro, Small, and Medium Enterprises (MSMEs), the Food and Drug Administration (FDA) officially partnered with the Provincial Government of Northern Samar (PGNS) through the signing of a Memorandum of Agreement (MOA) for the Bigyang-Halaga, Bangon MSMEs (BBMSMEs) Program on March 7, 2025, at Sumuroy Hall, Provincial Capitol. This collaboration marks a significant step in FDA’s commitment to strengthening food safety standards and regulatory compliance among local businesses. Through the BBMSMEs Program, FDA will provide technical assistance, capacity-building initiatives, and regulatory support to ensure that Northern Samar’s MSMEs adhere to Good Manufacturing Practices (GMP) and other essential safety protocols. By streamlining processes for obtaining Authorizations such as License to Operate (LTO) and Certificate of Product Registration (CPR), the program aims to expand market opportunities for local entrepreneurs. FDA Director General Dr. Samuel Zacate emphasized the agency’s proactive role in widening the program’s reach beyond Northern Samar. “Our goal is to empower MSMEs not only in this province but across the country by enhancing their access to regulatory services. Through collaborations with local government units (LGUs), the Department of Science and Technology (DOST), the Department of Trade and Industry (DTI), and state universities, we will facilitate laboratory testing, capacity-building programs, and a more efficient regulatory compliance system,” he stated. The initiative has been welcomed by local MSMEs and partner agencies, recognizing it as a key driver in positioning Northern Samar’s products in both national and global markets. The province, home to 4,458 MSMEs contributing 21.6% to its Gross Domestic Product (GDP), acknowledges their critical role as the backbone of the local economy. With this strengthened alliance, the FDA reaffirms its mission to uplift MSMEs, foster economic resilience, and build a more competitive business landscape. By prioritizing food safety and regulatory excellence, the agency remains steadfast in its commitment to ensuring that Filipino products meet the highest standards, paving the way for sustainable growth and broadening opportunities for local businesses. The MOA signing ceremony was attended by key officials, including Governor Edwin Ongchuan, Vice Governor Clarence Dato, Congressman Harris Ongchuan, Board Member Christian Emmanuel Uy, Department Head Jhon Allen B. Berbon, and FDA OIC-Deputy Director General Jesusa Joyce Cirunay and Visayas Cluster OIC-Director Rica Reina C. Aumentado. #FDA #BagongPilipinas #BagongMukhaNgFDA

724

The Food and Drug Administration Philippines Employees Association (FDAPEA) held the oath-taking ceremony for its newly elected officers on February 28, 2025. The event marked a significant milestone in the association’s commitment to advocating for the welfare of its members and strengthening its collaboration with the FDA leadership. The newly elected officers, led by President Archie SA Pielago, included Vice President Raymond L. Sia, Secretary Esperanza O. Almenanza, Treasurer Walter A. Palacpac, Auditor Antoinette A. Lapuz, and Public Relations Officer Marly P. Catalan. Joining them as board members were Carmencita M. Carreon, Gerson G. Bagood, August R. Manalo, Erjohn N. Ropero, Florita T. Descallar-Moraleja, and Marjorie M. Quiom. These dedicated individuals solemnly swore to uphold the constitution and by-laws of the association and to serve its members with integrity and commitment. The oath-taking was virtually officiated by FDA Philippines Director General Dr. Samuel A. Zacate, who underscored the importance of unity, integrity, and professionalism in his opening remarks. He emphasized the need for collaboration and mutual respect within the organization, expressing his confidence in the leadership of the newly elected set of officers to uphold transparency and dedication in serving the employees’ interests. Dr. Zacate’s presence at the event reinforced the agency’s commitment to fostering a strong partnership with the employees’ union. His support highlighted the FDA’s dedication to maintaining open communication and a harmonious working environment between management and staff, ensuring collective progress for the organization. The ceremony concluded with renewed optimism for a productive and cooperative relationship between FDAPEA and the FDA leadership, geared towards the continuous improvement of the agency and the well-being of its workforce. #FDA #BagongPilipinas #BagongMukhaNgFDA

721

#foryoupage #foodtok #FDA #CFRR #Educate #Regulate #Monitor

221

The Food and Drug Administration (FDA), through the Policy and Planning Service (PPS) -Policy Dissemination and Training Division (PDTD), recently held a webinar called “"Ngiting Healthy, Ngiting Wagi" to educate the public about the value of oral health. The webinar aimed to inform participants about the FDA's role in ensuring the safety of oral health care products, the best practices for maintaining oral health, and how to prevent oral health issues. Participants in the webinar included students and faculty members from various universities, local government units, and other government organizations. Ms. Estrellita B. Pastolero, Division Chief of the PDTD, welcomed the attendees and gave the opening remarks. One of the speakers, Dr. Alma Jane Aragon, an associate professor at the National University- College of Dentistry, talked about the common causes of oral health issues such as tooth decay and gum disease. Dr. Aragon emphasized that maintaining healthy teeth involves following a proper diet, practicing good oral hygiene, steering clear of harmful habits, and visiting the dentist regularly. Ms. Laarni P. Alberto, Food-Drug Regulation Officer III from the Center for Cosmetics Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR), explained the FDA regulations on oral health care products and the role of FDA in guaranteeing the safety and quality of oral health care products. An open forum ensued later which addressed the issues and concerns of the participants. #FDA #OralHealth #OralHealthMatters #FDAAdvocacy #Educate #Regulate #Monitor #fypage

225

The Food and Drug Administration (FDA) Philippines, under the leadership of Officer-in-Charge Deputy Director General for Field Regulatory Operations, Jesusa Joyce N. Cirunay, RPh, together with the Office of the Director General’s Chief of Staff, Atty. Nathaniel P. Liberato, convened a crucial meeting on 25 February 2025 at FDA Main Office Conference Hall with various industry associations and stakeholders in the medicinal products sector for both human and veterinary use. The discussion focused on the Pharmaceutical Inspection Co-operation Scheme (PIC/S), emphasizing the importance of compliance with its standards. FDA officials encouraged stakeholders to align with PIC/S guidelines, which would not only enhance their market authorization opportunities but also provide a competitive edge in the global pharmaceutical industry. An open forum was held, allowing stakeholders to raise concerns and receive direct responses from FDA officials, ensuring clarity on regulatory expectations. To strengthen collaboration, DDG Cirunay proposed regular monthly consultations, structured into two sessions—morning for human drug products and afternoon for veterinary medicines—to accommodate a broader audience. The FDA remains committed to fostering industry partnerships and advancing regulatory excellence as part of its mission to uphold public health and safety. #FDA #BagongPilipinas #BagongMukhaNgFDA

670

The Food and Drug Administration (FDA) recently held a meeting with the World Health Organization-Western Pacific Regional Office (WPRO) on February 27, 2025 at the FDA Conference Hall. The said meeting aimed to discuss strategies for enhancing the FDA’s Corrective and Preventive Actions (CAPA) system in alignment with the WHO Global Benchmarking Tool (WHO-GBT) standards. The discussions focused on identifying key areas where the FDA can improve its CAPA processes to ensure compliance with international regulatory benchmarks. This initiative is part of the broader effort to strengthen the agency’s regulatory functions and enhance its ability to address quality and safety concerns effectively. During the meeting, WHO-WPRO experts provided insights into best practices for CAPA implementation, emphasizing the importance of risk-based decision-making, robust documentation, and continuous monitoring. The WHO-WPRO team also conducted a site visit to the FDA Central Vaccine Laboratory which is currently undergoing construction. The tour provided an opportunity for WHO experts to assess the progress of the facility and offer recommendations to ensure that it meets international standards for vaccine testing and quality control. The FDA-WHO-WPRO meeting is part of the broader effort to strengthen the agency’s regulatory functions and enhance its ability to address safety and efficacy concerns effectively, thereby ensuring the quality of health products in the market. #FDA #WHO #WPRO #WHOGBT #Educate #Regulate #Monitor #fyppp

394

𝗞alayaang makapagpasya! 𝗞arapatang pumili! 𝗞akayahang pangalagaan ang sariling kalusugan at makapaghanda sa maayos na pagbuo ng pamilya Itaguyod ang “𝗙𝗮𝗺𝗶𝗹𝘆 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴” upang ang mga indibidwal o mag-partner ay magkakaroon nang malaya at responsableng desisyon sa bilang at sa pag-agwat sa pagitan ng mga anak. Sa pamamagitan ng 𝗙𝗮𝗺𝗶𝗹𝘆 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴, maisusulong rin ang proteksyon at pagpapatupad ng 𝗥𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝘃𝗲 𝗛𝗲𝗮𝗹𝘁𝗵 at ng pagtataguyod ng karapatan at kabutihan ng mga indibidwal lalo na ang mga kababaihan, Kabataan at mahihirap. Ang mga paraan ng 𝗙𝗮𝗺𝗶𝗹𝘆 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 ay ethical, non-abortifacient (hindi pampalaglag), accesible, legal, epektibo, ligtas, abot-kaya at may mataas na kalidad. Kita mo? Madaming paraan di ba? Kaya Kaya mo! #FDA #familyplanning #fypage #familytok

668

Biting Truth, Save Lives! 🦠🚫 Rabies Awareness Kontra Pekeng Bakuna—Alamin ang Katotohanang Nakakagigil! 🐶 #RabiesAwarenessMonth2025 #RabiesAwareness #FDA #FDAAdvovacy #Educate #Regulate #Monitor #fyp #pettok

279

The Food and Drug Administration (FDA) cordially invites you to join us for a webinar in celebration of Rabies Awareness Month. The webinar aims to provide participants with a comprehensive understanding of rabies, highlighting the FDA’s critical role in regulating rabies vaccines, and emphasizing measures to prevent the proliferation of counterfeit vaccines. WEBINAR DETAILS: 🐱🐈🐶🐕Rabies Awareness Month: "Biting Truth, Saving Lives: Rabies Awareness Kontra Pekeng Bakuna — Ang Katotohanang Nakakagigil" Date: Wednesday, March 12, 2025 Time: 9:00 AM - 12:00 NN Platform: Cisco Webex https://tinyurl.com/RAMWEBINAR Webinar Number: 2513 759 1455 Attendee Password: bESHAPjr273 (23742757 for phone/video system) #RabiesAwarenessMonth2025 #RabiesAwareness #FDA #WebinarAlert #pettok #fypシ゚

734

As part of its ongoing "Bigyang-Halaga Bangon MSMEs" (BBMSME) Program, the Food and Drug Administration (FDA) Philippines has officially partnered with Capiz State University (CAPSU) to support Micro, Small, and Medium Enterprises (MSMEs) nationwide through a Memorandum of Understanding (MOU) signed on February 13, 2025, at the Board Room of the Central Administration, CAPSU Main Campus, Roxas City. Leading the FDA delegation was OIC-Deputy Director General for Field Regulatory Operations Office, Jesusa Joyce N. Cirunay, accompanied by OIC–Director II for the Visayas Cluster, Rica Reina C. Aumentado. Representing CAPSU were University President Dr. Efren L. Linan, Vice President for Research, Development, and Extension (RDE) Dr. Leo Andrew B. Biclar, and University Director for Intellectual Property Management Prof. French A. Dampog. Also present were CAPSU-supported MSMEs (incubatees) and personnel from the CAPSU Agri-Aqua Technology Business Incubator (ATBI) and Agribusiness Incubator (ABI). The BBMSME Program aims to assist MSMEs in complying with regulatory requirements, securing FDA licenses and product registrations, and adopting Good Manufacturing Practices (GMP). Through this collaboration, the FDA will provide technical assistance and specialized training, empowering local entrepreneurs to compete not only in the domestic market but also in the global arena. During the event, DDG Cirunay reaffirmed the FDA’s commitment to supporting CAPSU’s incubatees, encouraging university researchers, professors, and students to go beyond research and bring their products to market. She emphasized the importance of leveraging FDA training programs to transform innovations into market-ready, FDA-compliant products. This milestone partnership reinforces the FDA’s dedication to fostering innovation and strengthening local industries by equipping MSMEs with the knowledge and resources necessary for success. For more information on BBMSMEs, visit the FDA website or follow the agency’s official social media channels. #FDA #BagongPilipinas #BagongMukhaNgFDA

905

The Food and Drug Administration (FDA) is advancing efforts to support micro, small, and medium enterprises (MSMEs) in Capiz. On February 13, 2025, FDA Deputy Director General Jesusa Joyce N. Cirunay, along with OIC Director II Rica Reina C. Aumentado and FDA Regional Supervisor Lemia A. Blances, met with Governor Fredenil H. Castro in Roxas City to discuss a strategic partnership aimed at strengthening local businesses. The primary goal of the meeting was to discuss the forgoing Memorandum of Agreement (MOA) for the launch of the Bigyan-Halaga, Bangon MSMEs (BBMSME) Program in Capiz. This initiative will provide Capiz MSMEs with essential support, including technical assistance, training, and guidance on complying with FDA regulations such as licenses, registrations, and food safety standards. The program is expected to enhance the province's businesses' competitiveness in both local and international markets. Governor Castro expressed strong backing for the collaboration, emphasizing its potential to boost Capiz's local economy. As the Seafood Capital of the Philippines, the province's marine resources are crucial to its economic growth, and the governor sees the partnership with the FDA as a key step toward sustaining the seafood industry and empowering the broader MSME sector. #FDA #BBMSME #Capiz #Educate #Regulate #Monitor #foryoupage

1023

Ang wastong kaalaman ang susi sa malusog na pangangatawan at upang Drug Overdose ay mapigilan. #FDA #DrugOverdose #FDAAdvocacy #Awareness #foryou #fypppp

299

RECAP | During the Meeting between FDA and DOST created by FDA Philippines with FDA Philippines’s original sound - FDA Philippines

310

Tulad ng mandato ng FDA, priyoridad ng ahensiya na gawing ligtas at de kalidad ang inyong mga gamot, pagkain at iba pang produktong pangkalusugan - ngayon, bukas at magpakailanman. #FDA #BagongPilipinas #BagongMukhaNgFDA

237

The Food and Drug Administration (FDA) is looking into strengthening its support for small businesses through a potential partnership with the University of the Philippines Mindanao (UP Mindanao). On January 23, 2025, FDA representatives led by Officer-In-Charge Deputy Director General for Field Regulatory Operations (OIC DDG FROO) Jesusa Joyce N. Cirunay, along with Mindanao East Cluster Director Deborah S. Legaspi and the FDA Regional Field Office XI Team, met with UP Mindanao officials to discuss this collaboration. They were welcomed by UP Mindanao Chancellor Lyre Anni Murao, College of Science and Mathematics Dean Cleto Nañola Jr., and Associate Professor Dann Marie del Mundo. The goal of this partnership is to help Micro, Small, and Medium Enterprises (MSMEs) improve their compliance with health and safety regulations. FDA’s Program Bigyang-Halaga, Bagong Micro, Small, and Medium Enterprises (BBMSME) aims to assist small businesses in meeting food safety standards so they can expand locally and internationally. As part of the proposed agreement, FDA will provide technical support to UP Mindanao to help its laboratories get accredited. The agency will also offer training programs including workshops, mentoring and skills development to enhance the university’s capabilities. Once accredited, UP Mindanao’s laboratory will be recognized as an official testing center for food products. One of the biggest challenges MSMEs face is the lack of access to affordable laboratory testing facilities. Without proper testing, many businesses struggle to meet safety standards, preventing them from selling their products in larger markets. This partnership aims to solve that problem by making laboratory services more accessible and affordable, especially for MSMEs in the Davao Region and the rest of the provinces in Mindanao. By combining FDA’s expertise in regulation with UP Mindanao’s research capabilities, this collaboration will open new opportunities for MSMEs while ensuring that food products meet safety and quality standards. If successful, this project could lead to more partnerships with other State Universities and Colleges (SUCs) in Mindanao, further boosting the region’s economic growth. #FDA #BagongPilipinas #BagongMukhaNgFDA

720

The Food and Drug Administration (FDA), led by Ms. Jesusa Joyce N. Cirunay, Director IV and Officer-in-Charge of the Office of the Deputy Director General for Field Regulatory Operations, met with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) on February 18, 2025, at the South Luzon-National Capital Region Cluster Conference Room in Alabang, Muntinlupa. The meeting focused on optimizing the Facilitated Review Pathway (FRP) to expedite access to essential medicines and medical devices. Other key topics included international regulatory collaboration, pharmacovigilance in Asia, and the relationship between the FDA and clinical trial sites. The session was led by the Policy and Planning Service - International Affairs Unit, headed by Mr. Ray Mark Morante, Senior Health Program Officer. Key attendees from the Philippines included representatives from the Office of the Director General, Center for Drug Regulation and Research, and Field Regulatory Operations Office. From the Japanese side, Dr. Kitahara Jun, Head of the PMDA Asia Office, was joined by Ms. Takemura Yuriko, Mr. Shimizu Kaito, and Dr. Aoki Fumiko, First Secretary of the Embassy of Japan in the Philippines. Discussions also covered upcoming PMDA-ASEAN meetings, international regulatory frameworks like the International Medical Device Regulators Forum (IMDRF), and plans for PMDA-ATC training in 2025. The meeting marked a significant step toward enhancing regulatory cooperation between the FDA and PMDA. Both agencies reaffirmed their commitment to improving drug and device evaluation processes and aligning these with global best practices. Future collaborations are expected to strengthen regulatory efficiency and expand international partnerships, ensuring better healthcare access for the general public in both countries. #FDA #PMDA #FRP #Educate #Regulate #Monitor #foryoupage #japan #philippines

600

The Food and Drug Administration (FDA), led by Director General Dr. Samuel A. Zacate, reaffirmed its support for First Lady Louise Araneta-Marcos' LAB for ALL program. This commitment was highlighted during the recent LAB for ALL event in Navotas City where the FDA Regional Field Office – National Capital Region (NCR) set up a booth alongside other government agencies. This aimed to provide the public with easy access to FDA services and other essential government programs, effectively bringing these services closer to the community. Also present at the LAB for ALL event were Officer-in-Charge Deputy Director General for Field Regulatory Operations Jesusa Joyce N. Cirunay, Atty. Nathaniel P. Liberato, Chief of Staff of the Office of the Director General, along with other FDA representatives and staff. #FDA #BagongPilipinas #BagongMukhaNgFDA

789

The Food and Drug Administration (FDA) reinforced its commitment to Intellectual Property Rights (IPR) by participating in a specialized training seminar on counterfeit detection on February 6, 2025, at Makati Diamond Residences. The event was organized by the Japan External Trade Organization (JETRO) in collaboration with the Japan Patent Office (JPO) and the Intellectual Property Office of the Philippines (IPOPHIL). As an active member of the National Committee on Intellectual Property Rights (NCIPR), the FDA joined Philippine authorities in discussions aimed at strengthening enforcement against counterfeit goods. The seminar sought to enhance cooperation between the Philippines and Japan by improving counterfeit detection skills and outlining guidelines for identifying infringing products. Representing the FDA’s commitment to IPR enforcement, members of the agency’s Technical Working Group (TWG) under FDA Oplan Katharos attended the event. Delegates included Atty. Vanessa G. Legasto (Chairman & Speaker), Mr. Raymond L. Sia (Co-Chair), and Mr. Archie S.A. Pielago (Vice Chair). Discussions emphasized fostering collaboration between Philippine agencies and Japanese companies holding intellectual property rights in the country. The FDA remains dedicated to protecting public health by combating counterfeit goods through strengthened anti-counterfeit measures and inter-agency cooperation. The agency continues to support initiatives that enhance enforcement capabilities and promote awareness of intellectual property rights. #FDA #IPOPHIL #NCIPR #OplanKatharos #Educate #Regulate #Monitor #fypageee

867

The Food and Drug Administration’s (FDA) Field Regulatory Operations Office (FROO) has reinforced its support for the Regulatory Enforcement Unit – Mindanao East Cluster (REU-MEC), ensuring sustained enforcement operations and financial backing for regulatory activities. Director Jesusa Joyce N. Cirunay, Officer-in-Charge of the Office of the Deputy Director General for Field Regulatory Operations, represented the FDA as an expert witness in a court hearing at the Regional Trial Court Branch 10, Ecoland, Davao City, on January 22, 2025. The case, filed by the National Bureau of Investigation – Southeastern Mindanao Regional Office in collaboration with the REU-MEC, targeted an establishment selling unregistered drugs and operating without an FDA-issued license, violating Section 11(a) and (k) of Republic Act (RA) No. 3720, as amended by RA No. 9711. Following the hearing, Director Cirunay convened a meeting with REU-MEC Special Investigators, Accountant April Dawn C. Molina, Administrative Officer IV Ivy M. Chatto, and Administrative Assistant II TA Anthony Ebreo. Despite the REU operating under the Legal Services Support Center’s supervision, Director Cirunay emphasized FROO’s commitment to ensuring proper budget allocation and effective resource management for REU operations. REU agents play a vital role in regulatory enforcement, conducting surveillance, inspections, and investigations to uphold FDA laws and regulations. During the meeting, Director Cirunay reaffirmed the FROO’s financial and administrative support for REU-MEC, ensuring the unit remains capable of fulfilling its mission to protect public health and maintain effective regulatory functions. The REU-MEC will continue to execute FDA’s quality policy by performing investigative and enforcement operations in collaboration with FDA Regional Field Offices, Local Government Agencies, and other law enforcement units. The FDA’s steadfast support aims to enhance regulatory compliance and sustain operations crucial to public safety. #FDA #FROO #REU #REUMEC #Educate #Regulate #Monitor #fyp

727

FDA at PNP-CIDG, Pinalakas ang Pagtutulungan Laban sa mga Pekeng Gamot at Hindi Rehistradong Produkto Pinamunuan ni Food and Drug Administration (FDA) Director General Samuel A. Zacate ang isang mahalagang pagpupulong na ginanap sa kanyang opisina kasama ang mga kinatawan ng Philippine National Police - Criminal Investigation and Detection Group (PNP-CIDG) sa pangunguna ni General Nicolas Torre noong Pebrero 13, 2025. Layunin nitong talakayin ang pagsasanib ng kanilang pwersa sa pagsugpo ng paglaganap ng mga pekeng gamot at mga hindi rehistradong produkto sa pamamagitan ng mas pinalakas ng inisyatiba ng FDA na tinatawag na "Oplan Katharos version 2" (OK2). Naging mahalagang hakbang ang Oplan Katharus upang protektahan ang mga konsyumer sa pamamagitan ng mahigpit na pagpapatupad ng mga regulasyon sa kalusugan. Sa pamamagitan ng mas matibay na alyansa sa pagitan ng FDA at PNP-CIDG, layunin nitong higit pang palakasin ang kanilang mga operasyon at palalimin ang kanilang ugnayan upang masupil ang mga lumalabag sa batas. Palalawakin din ang mga operasyon laban sa produksyon, distribusyon at pagbebenta ng pekeng gamot at substandard na mga produkto na nagdudulot ng seryosong banta sa kalusugan ng publiko. Bilang tugon sa lumalalang problema, binigyang-diin ng FDA at PNP-CIDG ang kahalagahan ng isang pinagsamang hakbang upang masubaybayan at mahuli ang mga nasa likod ng mga ilegal na gawain. Tinalakay din ang pagpapalakas ng mga operasyon laban sa mga ilegal na produkto na nagdudulot ng peligro sa kalusugan at kaligtasan ng mga mamamayan, kasabay ang pagtitiyak na pananagutin ang mga sindikato na nasa likod ng mga operasyong ito at ang paglipol sa kanilang mga mapanganib na produkto sa merkado. Dumalo rin sa pagpupulong ang mga pangunahing opisyal ng FDA kabilang sina Atty. Nathaniel P. Liberato, Chief of Staff ng Office of the Director General at Atty. Albertito C. Garcia ng Legal Services and Support Center. Naroon din ang mga kinatawan mula sa PNP-CIDG na nagpakita ng kooperasyon sa mga ahensya ng batas at mga regulatory agencies upang epektibong matugunan ang isyu ng pekeng gamot at hindi rehistradong mga produkto. Isang mahalagang hakbang ang istratehiyang pakikipagtulungan ng PNP-CIDG at FDA patungo sa pangako ng pamahalaang paigtingin ang estado ng kalusugan at kaligtasan ng publiko. Sa mas pinalawig na koordinasyon, patuloy nilang susuportahan ang isa't isa sa pagpapatupad ng mahigpit na regulasyon at operasyon na may layuning panatilihin ang kaligtasan ng bawat Pilipino. #FDA #BagongPilipinas #BagongMukhaNgFDA

1183

Sa mga may Valentine date ngayon: Siguraduhing ligtas, may tamang label, at walang hidden issues ang mga pagkain, gamot at iba pang health products na binibili. Maligayang Araw ng mga Puso! #FDA #BagongPilipinas #BagongMukhaNgFDA

736

In the interest of efficient public service delivery and to address concerns encountered in the implementation of Administrative Order No. 2024-0015 or the “Prescribing the Rules, Requirements and Procedures in the Application for License to Operate of Covered Health Product Establishments with the Food and Drug Administration Repealing for the Purpose Administrative Order No. 2020-0017”, the FDA is hereby informing our stakeholders that starting 17 February 2025, the filing of renewal applications for License to Operate (LTO) will be accepted within one hundred eighty (180) days prior to the expiration of their LTO’s original validity, instead of ninety (90) days. Read more:-> https://tinyurl.com/yupbnaey

797

#FDA #CFRR #FoodBorneIllnesses #fypage #Educate

318

The Food and Drug Administration (FDA) convened with the Department of Trade and Industry - Board of Investments (DTI-BOI) on February 12, 2025, for partnership towards better regulatory processes and further assistance to business owners. The meeting focused on streamlining procedures, addressing issues raised by investors, and improving coordination between the two agencies, particularly for industries being regulated by the FDA. Leading the FDA delegation was Dr. Irene Florentino-Fariñas, Director III of the Policy and Planning Service, along with Atty. Jehiel Jehaziel A. Serrano, Health Education and Promotion Officer IV of the Office of the Director General and technical representatives from various FDA Centers and Offices. Some of the key issues discussed included were more improved processing of License to Operate (LTO) and Certificate of Product Registration (CPR) applications, standardized assessment criteria to ensure consistency in the review process, accessibility of e-portal system, streamlining inspection schedules to minimize unnecessary delays while maintaining compliance, providing opportunities for direct consultations between FDA and investors and designating an assigned point of contact in each FDA center to respond efficiently to investor concerns. Recognizing the challenges posed by its aging e-portal system which currently struggles with bulk data and technical inefficiencies, the FDA-ICTMD acknowledged the need for an upgraded digital infrastructure. In response, DTI-BOI emphasized the importance of a Business Continuity Plan (BCP) to prevent processing disruptions and ensure smoother operations for stakeholders, as this challenge is not unique only to the FDA. The meeting also highlighted the progress in implementing Executive Order 18 (EO 18), which mandated the establishment of Green Lanes in government offices. These Green Lanes were designed to expedite, streamline, and automate regulatory processes for strategic investments, thereby enhancing business channels while upholding FDA’s stringent regulatory compliance requirements. This joint effort promotes a business-friendly environment, while also protecting public health and safety by easing regulatory barriers. This initiative reflects the FDA’s vision of “Bagong Pilipinas, Bagong Mukha ng FDA" and putting a premium on effectiveness, transparency and responsiveness that will improve services to stakeholders and the consuming public. #FDA #BOI #Educate #Regulate #Monitor #BagongPilipinas #BagongMukhaNgFDA #fyppppppppppppppppppppppp

232

Pormal nang nilagdaan ang kasunduan sa pagitan ng Food and Drug Administration (FDA) at Pamahalaang Panlalawigan ng Bohol ngayong ika-11 ng Pebrero 2025, Martes, sa Kapitolyo ng Bohol, na naglalayong magbukas ng mas malawak na oportunidad para sa mga maliliit na negosyo sa buong lalawigan. Pinangunahan ni Governor Aris Aumentado ang seremonya, kasama si FDA Director General Dr. Samuel A. Zacate. Sa okasyong ito, ipinakilala ang Proyektong "Bigyang Halaga, Bangon MSMEs" (BBMSME) na naglalayong palakasin at suportahan ang mga maliliit na negosyo sa pamamagitan ng pagtiyak na magiging FDA-approved ang bawat produktong pangkalusugan ng mga Boholano. Ipinahayag ni Governor Aumentado ang kanyang taos-pusong pasasalamat sa pamunuan ng FDA dahil isang malaking hakbang ito upang higit pang makilala at tangkilikin ang mga lokal na produkto ng lalawigan. Binigyang-diin niya na isang mahalagang pagkakataon din ito para mapalapit ang mga MSME (Micro, Small, and Medium Enterprises) ng Bohol sa mga pribadong kompanya na makatutulong sa pagpapalago ng kanilang kabuhayan at mas lalong mapalakas ang ekonomiya ng lalawigan. Ayon kay DG Zacate, may mahalagang ambag sa ekonomiya ng bansa ang bawat negosyante, maliit man o malaki. Nakatuon sa kanila ang pansin ng FDA dahil isa ito sa mga priyoridad ni Pangulong Ferdinand “Bongbong” Marcos Jr., na tinutugunan ng FDA. Layunin ng ahensiya na matutukan at matulungan ang mga MSMEs sa buong bansa upang maiangat ang antas ng kanilang kabuhayan bukod pa sa matiyak na laging ligtas, mabisa, at de kalidad ang kanilang mga produktong kinukunsomo ng publiko. Kabilang sa mga pumirma sina FDA OIC-Deputy Director General Jesusa Joyce N. Cirunay, OIC-Visayas Cluster Director Rica Reina C. Aumentado at kaniyang mga Supervisors, Provincial Administrator Ms. Asteria C. Caberte at isa sa mga Department Heads na si Ms. Maria Fe M. Dominise. #FDA #BagongPilipinas #BagongMukhaNgFDA

714

“NGIPING HEALTHY, NGITING WAGI” 🦷🦷🦷 Upang mapanatiling Malusog at Malinis ang Inyong Ngipin. #NationalDentalHealthMonth #Educate #Regulate #Monitor

768